Aktualne próby kliniczne, w których nasz Ośrodek bierze aktywny udział:

• ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: Dowiedz się więcej
• PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: Dowiedz się więcej
• OlympiA: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Dowiedz się więcej
• SOLO-1: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy Dowiedz się więcej

• SELINA:Prevention of Female Cancers by Optimization of Selenium Levels in the Organism: Dowiedz się więcej
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients: Dowiedz się więcej
•  VIOLETTE: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Dowiedz się więcej
• SOLO-2: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Dowiedz się więcej
• MONO-OLA1: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy: Dowiedz się więcej
• OReO: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Dowiedz się więcej
• SOLO-3: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments: Dowiedz się więcej
• LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients:  Dowiedz się więcej
• OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: Dowiedz się więcej